SCHEMBL16184228

SCHEMBL16184228

CNc1nc(-c2cnccn2)nc2c(OC)cc(-c3cc(Cl)ccc3Cl)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LIMK1 P53667 6/20 0.39
▸ LIMK2 P53671 6/20 0.39
▸ PTPN1 P18031 1/20 0.38
▸ MAT2A P31153 1/20 0.38
▸ CD38 P28907 1/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ TNF P01375 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MAPK1 P28482 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ SCN9A Q15858 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ PRKCQ Q04759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16184224 0.93 LIMK1 (0.38) LIMK1LIMK2PTPN1MAT2ACD38
SCHEMBL16184201 0.90 CYP1A2 (0.40) LIMK1LIMK2PTPN1MEN1KMT2A
SCHEMBL16184202 0.89 NPC1 (0.41) LIMK1LIMK2MAT2ACD38MEN1
SCHEMBL16184217 0.87 PDGFRB (0.39) LIMK1LIMK2CD38NPC1PKM
SCHEMBL16184225 0.87 LIMK1 (0.35) LIMK1LIMK2MAT2ACD38MEN1
SCHEMBL16184209 0.87 PTPN1 (0.37) LIMK1LIMK2PTPN1MAT2AALDH1A1
SCHEMBL16184207 0.86 MAP4K4 (0.43) MAT2AMEN1KMT2ATNFNPC1
SCHEMBL16184198 0.84 TGFBR1 (0.38) CD38NPC1RAB9AALDH1A1HPGD
SCHEMBL16184205 0.83 CYP3A4 (0.41) LIMK1LIMK2PTPN1ALDH1A1POLB
SCHEMBL14474205 0.83 TGFBR1 (0.35) LIMK1LIMK2CD38ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB LIMK1 1791/4885LIMK2 1319/4885PTPN1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback